Anca Gherman

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Kaja Abbas et autres

BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jaffar Abbas et autres

Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination of non-invasive …

Stratified analyses refine association between TLR7 rare variants and severe COVID-19

Jannik Boos, Caspar I. van der Made, Gayatri Ramakrishnan, Eamon Coughlan et autres

Despite extensive global research into genetic predisposition for severe COVID-19, knowledge on the role of rare host genetic variants and their relation to other risk factors remains limited.Here, 52 genes with prior etiological evidence were sequenced in 1,772 severe COVID-19 cases and …

de, nl, gb, it, es (code pays fourni par la source)

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Saul N. Faust, Richard Haynes, Christine E. Jones, Natalie Staplin et autres

BACKGROUND: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with …

us, de, gb (code pays fourni par la source)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner et autres

BackgroundThe EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression.We aimed to assess how effects of empagliflozin might differ by primary …

in, gb, de, us (code pays fourni par la source)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner et autres

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients.However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few …

gb (code pays fourni par la source)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres

BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …

A second update on mapping the human genetic architecture of COVID-19

Shea J. Andrews, Mattia Cordioli, Christine Stevens, Mark J. Daly et autres

Investigating the role of host genetic factors in COVID-19 severity and susceptibility can inform our understanding of the underlying biological mechanisms that influence adverse outcomes and drug development 1 , 2 . Here we present a second updated genome-wide association study (GWAS) …

us, fi, pl, my, ch, gb, Burkina Faso, ca, pr, it, in, Égypte, es, nl, Afrique du Sud, cl, hu, br, fr, be, mx, au, de, jp, py (code pays fourni par la source)

Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo‐Castineira, Konrad Rawlik, Andrew D. Bretherick, Ting Qi et autres

In the version of this article initially published, the name of Ana Margarita Baldión-Elorza, of the SCOURGE Consortium, appeared incorrectly (as Ana María Baldion) and has now been amended in the HTML and PDF versions of the article.

gb, cn, au, ca, ie, hk, es, mx, nl (code pays fourni par la source)

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo‐Castineira, Konrad Rawlik, Andrew D. Bretherick, Ting Qi et autres

Abstract Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown 1 to be highly efficient for discovery of genetic associations 2 . Despite the advanced stage of illness at presentation, we have shown that …

gb, cn, au, ca, ie, hk, es, mx, nl (code pays fourni par la source)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Joshua Abbas et autres

BACKGROUND: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. …

gb (code pays fourni par la source)